The Exercise And Colorectal Cancer Treatment Trial (EXACT)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This study will examine the biologic processes through which exercise may prevent disease recurrence in patients who have completed treatment for colorectal cancer.
Full description
This randomized trial will examine the biological effects of 12-weeks of moderate-intensity aerobic exercise versus wait-list control in 60 subjects who have completed standard medical therapy for colorectal cancer. The primary objective is to determine if aerobic exercise can reduce systemic inflammation, quantified using plasma concentrations of high-sensitivity C-reactive protein and interleukin-6. The secondary objectives are to determine if exercise can reduce: 1) insulin resistance quantified using an oral glucose tolerance test, and; 2) circulating tumor cells quantified using a microfluidic antibody-mediated capture platform. The exploratory objective is to determine if exercise can improve mitochondrial respiration rates and fatty acid oxidation in peripheral blood mononuclear cells and tumor fraction.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age ≥18 years
- Histologically-confirmed stage I-III colorectal cancer
- Completed surgical resection
- Completed chemotherapy (if applicable)
- Completed radiotherapy (if applicable)
- Provide written approval by physician or other qualified healthcare provider
- No planned major surgery during the study period (including colostomy reversal; chemotherapy infusion port removal is permitted)
- Readiness to exercise [as determined by a modified version the Physical Activity Readiness Questionnaire (PAR-Q)
- Allow the collection and storage of specimens and data for future use
- Willing to be randomized
Exclusion criteria
- Evidence of metastatic colon cancer
- Concurrently actively treated other cancer (except non-melanoma skin cancer or in situ cancers)
- Currently enrolled in another clinical trial of weight loss, physical activity, or dietary intervention
- Current body mass greater than or equal to 181 kg
- Unable to provide a baseline fasting blood sample
- Unable or unwilling to give informed consent
- Unable or unwilling to be randomized
- Or any other condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise program (as determined by the investigative team)
Trial design
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal